Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Business Wire (Tue, 1-Sep 8:30 AM ET)
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Business Wire (Fri, 14-Aug 4:05 PM ET)
Business Wire (Wed, 5-Aug 8:00 AM ET)
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Business Wire (Tue, 28-Jul 8:00 AM ET)
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Business Wire (Mon, 29-Jun 8:00 AM ET)
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Business Wire (Tue, 16-Jun 9:28 AM ET)
Market Chameleon (Mon, 20-Apr 5:52 AM ET)
Market Chameleon (Thu, 19-Feb 3:21 AM ET)
Market Chameleon (Fri, 12-Dec 3:35 AM ET)
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Enveric Biosciences trades on the NASDAQ stock market under the symbol ENVB.
As of September 11, 2026, ENVB stock price declined to $1.45 with 3,851 million shares trading.
ENVB has a beta of -0.04, meaning it tends to be less sensitive to market movements. ENVB has a correlation of 0.00 to the broad based SPY ETF.
ENVB has a market cap of $6.49 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ENVB traded as high as $525.60 and as low as $1.17.
The top ETF exchange traded funds that ENVB belongs to (by Net Assets): PSIL, VXF.
ENVB has underperformed the market in the last year with a return of -86.9%, while the SPY ETF gained +18.5%. In the last 3 month period, ENVB fell short of the market, returning -10.5%, while SPY returned +5.8%. However, in the most recent 2 weeks ENVB has outperformed the stock market by returning +5.8%, while SPY returned -0.7%.
ENVB support price is $1.38 and resistance is $1.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENVB shares will trade within this expected range on the day.